ClinicalTrials.gg
CompletedNCT05039021Updated Apr 30, 2025Results posted

A Prospective, Single-Arm Multi-Center Study of the HARMONIC® 1100 Shears in Select Devices

An interventional study of HARMONIC 1100 Shears in Pediatric Procedures, Adult Hepato-pancreato-biliary (HPB) Procedures and Adult Lower Gastrointestinal Procedures, sponsored by Ethicon Endo-Surgery. Completed at 7 sites in 3 countries. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by Ethicon Endo-Surgery (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
265
Allocation
Not applicable
Sex
All
01

Study summary

This prospective, single-arm, multi-center study will collect clinical data in a post-market setting for the pediatric population (general surgical procedures) and adult population (general, gynecological, urological, and thoracic surgical procedures). Investigators will perform each procedure using the device in compliance with their standard surgical approach and the HARMONIC 1100 Shears and Generator G11 instructions for use.

02

Conditions studied

  • Pediatric Procedures
  • Adult Hepato-pancreato-biliary (HPB) Procedures
  • Adult Lower Gastrointestinal Procedures
  • Adult Gastric Procedures
  • Adult Gynecological Procedures
  • Adult Urological Procedures
  • Adult Thoracic Procedures
03

In context

Lead sponsor

Ethicon Endo-Surgery is the lead sponsor of 47 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pediatric population:

  1. Non-emergent procedure (general) where at least one vessel is planned to be transected by the HARMONIC 1100 Shears per the IFU;
  2. Less than 18 years of age at the time of procedure; and
  3. The subject's parent/legal guardian must be willing to give permission for the subject to participate in the study and provide written for the subject. In addition, assent must be obtained from pediatric subjects who possess the intellectual and emotional ability to comprehend the concepts involved in the study. If the pediatric subject is not able to provide assent (due to age, maturity and/or inability to intellectually and/or emotionally comprehend the study), the parent/legal guardian's written informed consent for the subject will be acceptable for the subject to be included in the study.

Adult population:

  1. Elective procedure (general, gynecological, urological, or thoracic) where at least one vessel is planned to be transected by the HARMONIC 1100 Shears per the IFU;
  2. Willingness to give consent and comply with all study-related evaluations and visit schedule; and
  3. At least 18 years of age.

Exclusion criteria

Exclusion Criteria:

Preoperative

  1. Physical or psychological condition which would impair study participation;
  2. Female subjects, of childbearing age, who are pregnant; or
  3. Enrollment in a concurrent interventional clinical study that could impact the study endpoints.

Intraoperative

  1. The HARMONIC 1100 Shears were not attempted to be used for at least one single vessel transection during the surgical procedure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    Pediatric; adult (HPB, lower gastrointestinal, gastric, gynecological, urological, thoracic)

    Any pediatric or adult (hepato-pancreato-biliary, lower gastrointestinal, gastric, gynecological, urological, thoracic) procedures where the HARMONIC 1100 Shears is used for vessel transection according to instructions for use.

    Device: HARMONIC 1100 Shears

Interventions

  • DeviceHARMONIC 1100 Shears

    HARMONIC 1100 Shears is used for vessel transection according to instructions for use.

06

What researchers measure

Primary outcomes

  1. Number of Vessels Transected With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale

    Number of vessels transected with \<= Grade 3 hemostasis based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with HARMONIC 1100 Shears; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).

    Time frame: On the day of transection (Day 0)

  2. Number of Participants With Device-related Adverse Events (AEs)

    Number of participants with device-related AEs were reported. Device-related AEs were those AEs identified as having a relationship of possibly, probably, or causally with the study device. Possible refers to the relationship with the use of the device is weak but cannot be ruled out completely; Probable refers to the relationship with the use of the device seems relevant and/or the event cannot reasonably be explained by another cause, but additional information may be obtained; Causal relationship refers to the event is associated with the device or with procedures beyond reasonable doubt.

    Time frame: From Day 0 up to post-procedure follow up visit (up to 28 days)

Secondary outcomes

  1. Number of Vessels Transections With Diameter >5 to 7 mm With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale

    Number of vessels transected with diameter \>5 to 7 mm with \<= Grade 3 hemostasis based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with HARMONIC 1100 Shears; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).

    Time frame: On the day of transection (Day 0)

  2. Number of Participants Using HARMONIC 1100 Shears For Sealing and Transection of Lymphatic Vessels as Assessed by Surgeon Satisfaction Scale Score

    Number of participants using HARMONIC 1100 Shears for sealing and transection of lymphatic vessels as assessed by Surgeon Satisfaction Scale Score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for sealing and transection of lymphatic vessel by HARMONIC 1100 Shears.

    Time frame: On the day of transection (Day 0)

  3. Number of Vessels Transected With Hemostasis (Grade 1 to 4) Based on Hemostasis Grading Scale

    Number of vessels transected with hemostasis (Grade 1 to 4) based on hemostasis grading scale was reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with HARMONIC 1100 Shears; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).

    Time frame: On the day of transection (Day 0)

  4. Number of Grade 4 Vessel Transections Requiring Hemostasis Measures

    Number of Grade 4 vessel transections requiring hemostasis measures such as hemoclips, staples, sutures, fibrin sealants, adjunctive topical hemostats (except fibrin sealants), other advanced energy products and other products were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with HARMONIC 1100 Shears; or Grade 4: significant bleeding (pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (hemoclips, staples, sutures, fibrin sealants, adjunctive topical hemostats (except fibrin sealants), other advanced energy products). Since multiple responses were collected, sum of the data of each category exceeds the overall number of units analyzed.

    Time frame: On the day of transection (Day 0)

07

Results

Posted Mar 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneHARMONIC 1100 Shears
Started265
Completed261
Not completed4
Withdrew: Death1
Withdrew: Lost to follow-up3

Outcome measures

PrimaryNumber of Vessels Transected With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale

Number of vessels transected with \<= Grade 3 hemostasis based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with HARMONIC 1100 Shears; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).

Time frame:
On the day of transection (Day 0)
Reported as:
Count of units · Vessels transected
Number of Vessels Transected With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale
Vessels transectedHARMONIC 1100 Shears
Number of Vessels Transected With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale484
PrimaryNumber of Participants With Device-related Adverse Events (AEs)

Number of participants with device-related AEs were reported. Device-related AEs were those AEs identified as having a relationship of possibly, probably, or causally with the study device. Possible refers to the relationship with the use of the device is weak but cannot be ruled out completely; Probable refers to the relationship with the use of the device seems relevant and/or the event cannot reasonably be explained by another cause, but additional information may be obtained; Causal relationship refers to the event is associated with the device or with procedures beyond reasonable doubt.

Time frame:
From Day 0 up to post-procedure follow up visit (up to 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Device-related Adverse Events (AEs)
ParticipantsHARMONIC 1100 Shears
Number of Participants With Device-related Adverse Events (AEs)5
SecondaryNumber of Vessels Transections With Diameter >5 to 7 mm With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale

Number of vessels transected with diameter \>5 to 7 mm with \<= Grade 3 hemostasis based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with HARMONIC 1100 Shears; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).

Time frame:
On the day of transection (Day 0)
Reported as:
Count of units · Vessels transected
Number of Vessels Transections With Diameter >5 to 7 mm With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale
Vessels transectedHARMONIC 1100 Shears
Number of Vessels Transections With Diameter >5 to 7 mm With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale174
SecondaryNumber of Participants Using HARMONIC 1100 Shears For Sealing and Transection of Lymphatic Vessels as Assessed by Surgeon Satisfaction Scale Score

Number of participants using HARMONIC 1100 Shears for sealing and transection of lymphatic vessels as assessed by Surgeon Satisfaction Scale Score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for sealing and transection of lymphatic vessel by HARMONIC 1100 Shears.

Time frame:
On the day of transection (Day 0)
Reported as:
Count of participants · Participants
Number of Participants Using HARMONIC 1100 Shears For Sealing and Transection of Lymphatic Vessels as Assessed by Surgeon Satisfaction Scale Score
ParticipantsHARMONIC 1100 Shears
Very Satisfied76
Satisfied25
Neither Satisfied or Dissatisfied0
Dissatisfied0
Very Dissatisfied3
SecondaryNumber of Vessels Transected With Hemostasis (Grade 1 to 4) Based on Hemostasis Grading Scale

Number of vessels transected with hemostasis (Grade 1 to 4) based on hemostasis grading scale was reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with HARMONIC 1100 Shears; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).

Time frame:
On the day of transection (Day 0)
Reported as:
Count of units · Vessels transected
Number of Vessels Transected With Hemostasis (Grade 1 to 4) Based on Hemostasis Grading Scale
Vessels transectedHARMONIC 1100 Shears
Grade 1475
Grade 22
Grade 37
Grade 45
SecondaryNumber of Grade 4 Vessel Transections Requiring Hemostasis Measures

Number of Grade 4 vessel transections requiring hemostasis measures such as hemoclips, staples, sutures, fibrin sealants, adjunctive topical hemostats (except fibrin sealants), other advanced energy products and other products were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with HARMONIC 1100 Shears; or Grade 4: significant bleeding (pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (hemoclips, staples, sutures, fibrin sealants, adjunctive topical hemostats (except fibrin sealants), other advanced energy products). Since multiple responses were collected, sum of the data of each category exceeds the overall number of units analyzed.

Time frame:
On the day of transection (Day 0)
Reported as:
Count of units · Vessels transected
Number of Grade 4 Vessel Transections Requiring Hemostasis Measures
Vessels transectedHARMONIC 1100 Shears
Hemoclips4
Staples1
Sutures0
Fibrin Sealants0
Adjunctive Topical Hemostats (except Fibrin Sealants)1
Other Advanced Energy Products1
Other1

Adverse events

Collected over From Day 0 up to post-procedure follow up visit (Up to 28 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HARMONIC 1100 Shears1/265 (0.4%)16/265 (6%)69/265 (26%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventHARMONIC 1100 Shears
Small intestinal obstructionGastrointestinal disorders2/265
PneumothoraxRespiratory, thoracic and mediastinal disorders2/265
Acute myocardial infarctionCardiac disorders1/265
Pericardial effusionCardiac disorders1/265
TachycardiaCardiac disorders1/265
Abdominal pain lowerGastrointestinal disorders1/265
NauseaGastrointestinal disorders1/265
EmpyemaInfections and infestations1/265
PneumoniaInfections and infestations1/265
Post procedural pneumoniaInfections and infestations1/265
Most frequent other events
Showing 10 of 86
Most frequent other events
EventHARMONIC 1100 Shears
NauseaGastrointestinal disorders9/265
PainGeneral disorders8/265
Abdominal painGastrointestinal disorders7/265
Wound infectionInfections and infestations5/265
Procedural painInjury, poisoning and procedural complications5/265
AnaemiaBlood and lymphatic system disorders4/265
Abdominal tendernessGastrointestinal disorders4/265
PneumothoraxRespiratory, thoracic and mediastinal disorders4/265
HypotensionVascular disorders4/265
Abdominal distensionGastrointestinal disorders3/265

Baseline characteristics

Age, Continuous
Age, Continuous(years)HARMONIC 1100 Shears
Mean53.73 ± 22.793
Sex: Female, Male
Sex: Female, Male(Participants)HARMONIC 1100 Shears
Female158
Male107
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HARMONIC 1100 Shears
Hispanic or Latino5
Not Hispanic or Latino224
Unknown or Not Reported36
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HARMONIC 1100 Shears
American Indian or Alaska Native0
Asian8
Native Hawaiian or Other Pacific Islander0
Black or African American29
White213
More than one race0
Unknown or Not Reported15
08

Study locations

7 sites
  • Baptist Health
    Jacksonville, Florida 32207, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • IU Health University Hospital
    Indianapolis, Indiana 46202, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Centre Hospitalier de l'Universite de Montreal
    Montreal, Canada
  • Toronto General Hospital
    Toronto, Canada
  • Western General Hospital
    Edinburgh, Scotland, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu

Data sharing details ↗ · yoda.yale.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Feb 2024, 30 months.

Results were first posted in Mar 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2021
First posted
Sep 9, 2021
StartActual
Jul 29, 2021
Primary completionActual
Feb 4, 2024
CompletionActual
Mar 12, 2024
Results first posted
Mar 12, 2025
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05039021
Responsible party
Sponsor
First posted
Sep 9, 2021
Start date
Jul 29, 2021
Primary completion
Feb 4, 2024
Completion
Mar 12, 2024
Results posted
Mar 12, 2025
Last update
Apr 30, 2025

Study contacts

Ethicon Endo-Surgery Clinical Trial
study director · Ethicon Endo-Surgery
Troy Markel, MD
principal investigator · Riley Hospital for Children at Indiana University Health
Attila Nakeeb, MD
principal investigator · IU Health University Hospital
Moishe Liberman, MD
principal investigator · Centre Hospitalier de l'Universite de Montreal

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion